
Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2008; month=1; day=23; hr=16; min=23; sec=52; ms=790;]

Validated By CRFValidator v 1.0.3

Application No: 10505239 Version No: 3.0

Input Set:

Output Set:

Started: 2008-01-14 15:41:32.403 **Finished:** 2008-01-14 15:41:34.181

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 778 ms

Total Warnings: 28
Total Errors: 0

No. of SeqIDs Defined: 28

Actual SeqID Count: 28

Error code		Error Description									
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(1)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(2)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(3)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(4)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(5)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(6)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(7)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(8)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(9)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(10)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(11)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(12)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(13)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(14)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(15)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(16)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(17)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(18)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(19)
W	213	Artificial	or	Unknown	found	in	<213>	in	SEQ	ID	(20)

Input Set:

Output Set:

Started: 2008-01-14 15:41:32.403

Finished: 2008-01-14 15:41:34.181

Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 778 ms

Total Warnings: 28

Total Errors: 0

No. of SeqIDs Defined: 28

Actual SeqID Count: 28

Error code Error Description

This error has occured more than 20 times, will not be displayed

SEQUENCE LISTING

```
<110> TARASOVA, Nadya I
      MICHEJDA, Christopher J
      DYBA, Marcin
      COHRAN, Carolyn
<120> CONJUGATES OF LIGAND, LINKER AND CYTOTOXIC AGENT AND RELATED
      COMPOSITIONS AND METHODS OF USE
<130> 229694
<140> 10505239
<141> 2004-10-12
<150> PCT/US03/06344
<151> 2003-02-27
<150> 60/360,543
<151> 2002-02-27
<150> 60/370,189
<151> 2002-04-05
<160> 28
<170> PatentIn version 3.4
<210> 1
<211> 4
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 1
Phe Ala Leu Ala
<210> 2
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 2
Val Leu Ala Leu Ala
```

```
<210> 3
<211> 4
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 3
Ala Leu Ala Leu
<210> 4
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 4
Ala Leu Ala Leu Ala
<210> 5
<211> 33
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 5
Leu Gly Pro Gln Gly Pro Pro His Leu Val Ala Asp Pro Ser Lys Lys
                                10
Gln Gly Pro Trp Leu Glu Glu Glu Glu Glu Ala Tyr Gly Trp Met Asp
         20
                        25
Phe
<210> 6
<211> 4
<212> PRT
<213> Artificial
<220>
```

<223> Synthetic

```
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa = at position 2 is norleucine
<400> 6
Trp Xaa Asp Phe
<210> 7
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa = at position 2 is sulfotyrosine
<400> 7
Asp Xaa Met Gly Trp Met Asp Phe
              5
<210> 8
<211> 8
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa = at position 2 is sulfotyrosine
<220>
<221> misc_feature
<222> (3)..(3)
<223> Xaa = at position 3 is norleucine
<220>
<221> misc_feature
<222> (6)..(6)
<223> Xaa = at position 6 is norleucine
```

```
Asp Xaa Xaa Gly Trp Xaa Asp Phe
<210> 9
<211> 27
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 9
Val Pro Leu Pro Ala Gly Gly Gly Thr Val Leu Thr Lys Met Tyr Pro
1 5
                   10
Arg Gly Asn His Trp Ala Val Gly His Leu Met
                           25
          20
<210> 10
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 10
Trp Ala Val Gly His Leu Met
1 5
<210> 11
<211> 14
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 11
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
                               10
<210> 12
<211> 8
<212> PRT
```

<400> 8

<213> Artificial

```
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(8)
<223> wherein the peptide is carboxylated at either the N-or C-
      terminus
<400> 12
Phe Cys Phe Trp Lys Thr Cys Thr
<210> 13
<211> 11
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 13
Arg Pro Leu Pro Gln Gln Phe Phe Gly Leu Met
    5
                                10
<210> 14
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 14
Pro Gly Thr Cys Glu Ile Cys Ala Tyr Ala Ala Cys Thr Gly Cys
               5
                                  10
                                                     15
<210> 15
<211> 14
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<400> 15
Asn Asp Asp Cys Glu Leu Cys Val Ala Cys Thr Gly Cys Leu
            5
                                10
```

<220>

```
<210> 16
<211> 16
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic
<400> 16
Asn Tyr Cys Cys Glu Leu Cys Cys Asn Pro Ala Cys Thr Gly Cys Phe
                     10
<210> 17
<211> 29
<212> PRT
<213> Artificial Sequence
<220>
<223> Synthetic
<400> 17
His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln
               5
                                 10
Met Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly
         20
                             25
<210> 18
<211> 29
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (17)..(17)
<223> Xaa = at position 17 is norleucine
<400> 18
His Ser Asp Ala Leu Phe Thr Asp Asn Tyr Thr Arg Leu Arg Leu Gln
```

Xaa Ala Val Lys Lys Tyr Leu Asn Ser Ile Leu Asn Gly
20 25

```
<210> 19
<211> 7
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (5)..(5)
<223> Xaa = at position 5 is norleucine
<400> 19
Ala Tyr Gly Trp Xaa Asp Phe
      5
<210> 20
<211> 10
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa = at position 8 is norleucine
<400> 20
Glu Glu Glu Ala Tyr Gly Trp Xaa Asp Phe
          5
                                  10
<210> 21
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa = at position 1 is 2-cyclohexyl-L-alanine
<400> 21
```

Xaa Leu Ala Leu Ala

1 5

```
<210> 22
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa = at position 1 is 2-cyclohexyl-L-alanine
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa = at position 2 is 2-cyclohexyl-L-alanine
<400> 22
Xaa Xaa Leu Ala Leu
<210> 23
<211> 5
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa = at position 1 is 1-naphtyl-alanine
<220>
<221> misc_feature
<222> (2)..(2)
<223> Xaa = at position 2 is 2-cyclohexyl-L-alanine
<400> 23
Xaa Xaa Leu Ala Leu
<210> 24
<211> 5
<212> PRT
<213> Artificial
```

```
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa = at position 1 is 1-naphtyl-alanine
<400> 24
Xaa Leu Ala Leu Ala
<210> 25
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa = at position 13 is norleucine
<400> 25
Val Leu Ala Leu Ala Glu Glu Ala Tyr Gly Trp Xaa Asp Phe
              5
                                   10
                                                       15
<210> 26
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> V = at position 1 is conjugated to SPA110
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa = at position 13 is norleucine
<220>
<221> misc_feature
```

```
<223> F = at position 15 comprises a C-terminal amide group
<400> 26
Val Leu Ala Leu Ala Glu Glu Ala Tyr Gly Trp Xaa Asp Phe
                                   10
<210> 27
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (1)..(1)
<223> Xaa = at position 1 is 2-cyclohexyl-L-alanine and is conjugated
      to HTI-286
<220>
<221> misc_feature
<222> (13)..(13)
<223> Xaa = at position 13 is norleucine
<220>
<221> misc_feature
<222> (15)..(15)
<223> F = at position 15 comprises a C-terminal amide group
<400> 27
Xaa Leu Ala Leu Ala Glu Glu Ala Tyr Gly Trp Xaa Asp Phe
               5
                                   10
                                                       15
<210> 28
<211> 14
<212> PRT
<213> Artificial
<220>
<223> Synthetic
<220>
<221> misc_feature
<222> (12)..(12)
<223> Xaa = at position 12 is norleucine
<400> 28
```

Phe Ala Leu Ala Glu Glu Glu Ala Tyr Gly Trp Xaa Asp Phe

<222> (15)..(15)

1 5 10